Breaking News

BioMarin Acquires ZyStor Therapeutics

BioMarin Pharmaceutical has acquired ZyStor Therapeutics for $22 million upfront and as much as an additional $93 million if certain development, regulatory and commercial milestones are achieved.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioMarin Pharmaceutical has acquired ZyStor Therapeutics for $22 million upfront and as much as an additional $93 million if certain development, regulatory and commercial milestones are achieved. ZyStor is a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor’s lead product candidate ZC-701 is a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters